Virtual Sexual Health and Rehabilitation eClinic for Prostate Cancer Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of SHAReClinic, a national virtual eClinic aimed at supporting prostate cancer patients and their partners in managing sexual health issues post-treatment. The study assesses the impact of guided education modules and sexual health counseling on improving sexual function, satisfaction, and relational intimacy. By expanding access to sexual health care, SHAReClinic seeks to address the significant unmet needs of prostate cancer survivors and their partners across Canada. The findings will contribute to best practices in survivorship care and help establish a national standard for oncology sexual health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who are scheduled for first-line treatment for localized prostate cancer, either through radical prostatectomy (open or robotic) or radiation treatment (brachytherapy, external beam) Alone, or with adjuvant Androgen Deprivation Therapy (ADT) OR

  * Patients currently undergoing active treatment for prostate cancer OR
  * Patients who have undergone cancer treatment in the past 6 months
  * Patients who are hormone and/or chemotherapy-naïve
  * Patients who have access to a computer or smartphone with internet access
  * Patients who are 18 years of age or older

Exclusion Criteria:

* Patients on ADT alone as primary treatment, and/or patients on chemotherapy
* Patients who lack English proficiency
* Patients on nitrate therapy or have other contra-indications to phosphodiesterase type 5 inhibitors (PDE5i's)
* Patients with medical conditions that would preclude safe sexual activity
* Patients who have had previous treatment for PCa

Where it's running

• Vancouver Coastal Health Authority
  Vancouver, British Columbia, Canada Recruiting
• Men's Health Clinic Manitoba
  Winnipeg, Manitoba, Canada Recruiting
• Royal Victoria Regional Health Centre
  Barrie, Ontario, Canada Recruiting
• Kingston Health Sciences Centre
  Kingston, Ontario, Canada Recruiting
• Grass Family Men's Health Center
  Ottawa, Ontario, Canada Recruiting
• University Health Network
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Andrew Matthew, PhD. C.Psych — Princess Margaret Cancer Centre
• Study coordinator: Steven Guirguis, MA
• Email: steven.guirguis@uhn.ca
• Phone: 416-946-4501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry assessing PSMA PET outcomes in prostate cancer

  This study is testing if PSMA PET imaging can help doctors better understand the outcomes for men with prostate cancer compared to traditional methods.

  Recruiting University Hospital, Essen · Essen · NCT06320223

• PRP injection for female sexual function

  This trial tests whether a patient’s own PRP injection into the front vaginal wall can improve sexual function in women with sexual dysfunction.

  Recruiting Icahn School of Medicine at Mount Sinai · New York, New York · NCT07920900

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.